Skip to main content

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.

Translational Neurodegeneration operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Edited by Shengdi Chen, Translational Neurodegeneration is supported by an expert Editorial Board. Manuscripts are reviewed by internationally recognized experts in the field, selected in part from the journal's Editorial Board. The suitability of manuscripts for publication is assessed solely on criteria of scientific excellence: final decisions are made by the Editor-in-Chief and may include accept, reject, accept following minor revision and resubmit after major revision and further review.

Affiliated with

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 10.8
    5-year Journal Impact Factor: 11.6
    Source Normalized Impact per Paper (SNIP): 2.374
    SCImago Journal Rank (SJR): 3.371

    Speed 2023
    Submission to first editorial decision (median days): 7
    Submission to acceptance (median days): 111

    Usage 2023
    Downloads: 767,289
    Altmetric mentions: 3,389